Last reviewed · How we verify
Coaxil (tianeptine)
Tianeptine works by binding to the mu-type opioid receptor, which can affect the brain's response to pain and emotions.
Tianeptine, marketed as Coaxil by Pfizer, currently holds no approved indications and has not conducted any clinical trials, positioning it outside the mainstream antidepressant market. Its unique mechanism of action, involving the mu-type opioid receptor, distinguishes it from key competitors such as tryptophan, nomifensine, trazodone, nefazodone, and viloxazine. A significant risk is the lack of clinical data and approved indications, which may limit its market potential and adoption by healthcare providers. The pipeline outlook remains uncertain due to the absence of ongoing clinical trials and the requirement for a PD-L1 companion diagnostic for several potential indications.
At a glance
| Generic name | tianeptine |
|---|---|
| Sponsor | Pfizer |
| Drug class | tianeptine |
| Target | Mu-type opioid receptor |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Imagine your brain has a special lockbox that controls how you feel pain and emotions. Tianeptine is a key that fits into this lockbox, which can help change how the lockbox works. This can lead to changes in how you feel pain and emotions, but it's not fully understood how it works.
Approved indications
Common side effects
- Somnolence
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Coaxil CI brief — competitive landscape report
- Coaxil updates RSS · CI watch RSS
- Pfizer portfolio CI